

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARCBDF (subcut)

(Page 1 of 3)

DOCTOR'S ORDERS	Ht	cm	Wt	kg	BSA_	m²
REMINDER: Please ensure drug allergies and previous	s bleomycin a	re docum	ented o	n the Allergy	& Alert F	orm
DATE: To be give	n:			Cycle #:		
Date of Previous Cycle:						
**** Ensure Red Blood Cell Phenotype and Group an Delay treatment week(s) CBC & Diff, platelets day of treatment	nd Screen for	all patier	nts prior	to Cycle 1**	**	
Proceed with all medications for entire cycle as written, if within 96 hours of Day 1: ANC greater than or equal to 0.5 x 10 ⁹ /L, platelets greater than or equal to 50 x 10 ⁹ /L, total bilirubin less than or equal to 1.5 x upper limit of normal, and eGFR or creatinine clearance per protocol						
Dose modification for: Hematology:		□ Ot	her Tox	cicity:		
Proceed with treatment based on blood work from						
CHEMOTHERAPY:						
CYCLOPHOSPHAMIDE – Cycles 1 to 9						
☐ cyclophosphamide 500 mg PO once weekly in to <i>OR</i>	the morning o	n Days 1	, 8, 15 a	and 22. Dispe	ense	cycles.
cyclophosphamide mg PO once weekly i	in the morning	g on Days	S	D	spense	cycles.
cyclophosphamide 50 mg PO once in the morni	ng every 2 da	ays for	dos	ses. Disper	se	cycles
BORTEZOMIB – Cycles 1 to 9 Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily						
bortezomib 1.5 mg/m² or 1.3 mg/m² or 1 mg/m² or 0.7 mg/m² or 0.5 mg/m² (select one) x BSA = mg						
subcutaneous injection weekly on Days 1, 8, 15 and	22					
STEROID: RN to use patient's therapeutic steroid (if applicable) as pre-med for daratumumab - refer to protocol Cycles 1 to 9						
dexamethasone 40 mg or 20 mg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, <i>OR</i>						
dexamethasonemg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning, <i>OR</i>						
predniSONEmg PO once weekly on Days 1, 8, 15 and 22. Take dose prior to daratumumab and on weeks without daratumumab, take dose in the morning						
☐ No steroid						
DOCTOR'S SIGNATURE:				SIGN	ATURE	<u> </u>
				UC:		



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARCBDF (subcut)

(Page 2 of 3)

DATE:						
**Have Hypersensitivity Reaction Tray and Protocol Av						
Insert a peripheral IV and saline lock for Cycle 1 Day 1 only for use in the event	or a hypersensitivity reaction.					
DARATUMUMAB						
 Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily 						
DARATUMUMAB PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm.						
dexamethasone as ordered in steroid section						
montelukast 10 mg PO prior to daratumumab on Cycle 1 Day 1 montelukast 10 mg PO prior to each daratumumab						
acetaminophen 650 mg PO prior to each daratumumab. Repeat acetaminophen 650 mg PO every 4 hours when						
needed						
Select one of the following:						
☐ loratadine 10 mg PO prior to each daratumumab, then diphenhydrAMINE 50 mg IV every 4 hours when needed						
OR						
☐ diphenhydrAMINE 50 mg ☐ PO or ☐ IV prior to each daratumumab. Repeat diphenhydrAMINE 50 mg IV every 4 hours when needed						
DARATUMUMAB						
☐ CYCLE # 1, Days 1, 8, 15 and 22:						
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*						
☐ CYCLE # 2, Days 1, 8, 15 and 22: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*						
☐ CYCLES 3 to 6, Days 1 and 15: daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen	over 5 minutes*					
☐ CYCLES 7 to 9, Day 1:						
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*						
an analy and a second of the s						
☐ CYCLE 10 onwards, Day 1:						
daratumumab subcut 1800 mg (fixed dose in 15 mL) subcutaneously into abdomen over 5 minutes*						
	x cycle(s) (max 3 cycles)					
*Observe patient for 1 hour after administration on Day 1 of Cycle 1 only. For patients switching from IV daratumumab, observe for 30 minutes after the first subcutaneous dose. Observation not required on subsequent doses unless requested by physician. Vital signs immediately prior to and at the end of injection, and at end of observation period of first injection only, and as needed.						
NB: During treatment with subcutaneous daratumumab, administer other subcutaneous drugs at possible.	alternative injection sites whenever					
DOCTOR'S SIGNATURE:	SIGNATURE:					
	UC:					



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYDARCBDF (subcut)

(Page 3 of 3)

DATE:					
RETURN APPOINTMENT ORDERS					
For Cycles 1 to 9 book chemo on Days 1, 8, 15, 22 For Cycles 10 and subsequent, book chemo on Day 1 Return in four weeks for Doctor and Cycle Return in eight weeks for Doctor and Cycles and Book chemo x 2 cycles.					
 ☐ Return in twelve weeks for Doctor and Cycles, and Book chemo x 3 cycles ☐ Last Cycle. Return in week(s). 					
CBC & Diff, platelets, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis and serum free light chain levels every 4 weeks Urine protein electrophoresis every 4 weeks					
☐ Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks					
☐ Beta-2 microglobulin every 4 weeks					
☐ CBC & Diff, platelets Days 8, 15, 22					
☐ Creatinine, sodium, potassium Days 8, 15, 22					
☐ Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22					
☐ Random glucose Days 8, 15, 22					
☐ Calcium, albumin Days 8, 15, 22					
☐ See general orders sheet for additional requests					
Other tests:					
☐ Consults					
DOCTOR'S SIGNATURE:	SIGNATURE:				
	UC:				